Deerfield Capital Management
Venture capital · New York, New York, United States
Portfolio collected from the firm’s website, last checked Jun 28, 2026.Raises and exits come from each company’s own SEC and company records.
18Deep-tech portfolio8 active
10Portfolio exitsAcquired or listed
1Raises, 12 monthsLatest: Relation Therapeutics
72Co-investorsShare a portfolio company
Portfolio · 18 companies
| Company | Sector | Status | Latest raise | Raised |
|---|---|---|---|---|
| Relation Therapeutics | Biotech | Active | Dec 9, 2025 | $116.4M |
| Elion Therapeutics | Biotech | Active | Jun 26, 2024 | $25.4M |
| Prelude Therapeutics | Biotech | Active | Aug 28, 2020 | $97.0M |
| AP Neomorph | Biotech | Active | — | — |
| Excelsior Sciences | Biotech | Active | — | — |
| Kalaris Therapeutics | Biotech | Active | — | — |
| Neomorph | Biotech | Active | — | — |
| Roivant Sciences | Biotech | Active | — | — |
| Immunovant | Biotech | Public | Jan 21, 2025 | $450.0M |
| Alumis | Biotech | Public | Jul 24, 2024 | $240.0M |
| Voyager Therapeutics | Biotech | Public | Jan 17, 2024 | $119.0M |
| Relay Therapeutics | Biotech | Public | Jan 10, 2024 | $30.0M |
| Septerna | Biotech | Public | Jul 13, 2023 | $73.5M |
| Decibel Therapeutics | Biotech | Acquired | Nov 12, 2020 | $62.8M |
| Nuvation Bio | Biotech | Public | Oct 20, 2020 | $275.3M |
| Passage Bio | Biotech | Public | Sep 6, 2019 | $110.0M |
| Scholar Rock | Biotech | Public | Jan 4, 2016 | $36.3M |
| Praxis Precision Medicine | Biotech | Public | — | — |
Peer ranks
Portfolio size#21
Portfolio exits#11
Raises, 12 months#22
Co-investors#8
Co-investors
- Third Rock VenturesVenture capital6 shared
- Boxer CapitalVenture capital4 shared
- Perceptive Life SciencesVenture capital4 shared
- EcoR1 CapitalVenture capital3 shared
- GVVenture capital3 shared
- Omega FundsVenture capital3 shared
- Perceptive AdvisorsVenture capital3 shared
- RTW InvestmentsVenture capital3 shared
- Andreessen HorowitzVenture capital2 shared
- Ascent Biomedical VenturesVenture capital2 shared
Sectors
- Biotech18
Portfolios are collected from investors’ own websites and matched to tracked deep-tech companies by name; duplicate listings of the same firm are merged. Exits and raises come from each company’s own record: Form D through the latest filing.